Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer-Reference-Cited by-同舟云学术

Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer

Published:2023-01-24 Issue:3 Volume:66 Page:1725-1741
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhang Qiangsheng¹,Chen Xinyi¹,Cao Jiaying¹,Yang Wan¹,Wan Guoquan¹,Feng Qiang²,Zhou Shuyan¹,Yang Hongling¹,Wang Ningyu³,Liu Zhihao¹⁴,Xiao Hongtao⁵,Zhu Yongxia⁵,Yu Luoting¹

Affiliation:

1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, 17#3rd Section, Ren Min South Road, Chengdu 610041, P. R. China

2. College of Chemistry and Life Science, Chengdu Normal University, Chengdu 611130, P. R. China

3. School of Life Science and Engineering, Southwest JiaoTong University, Chengdu 611756, Sichuan, P. R. China

4. Laboratory of Emergency Medicine, Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

5. Department of Clinical Pharmacy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, P. R. China

Funder

Department of Science and Technology of Sichuan Province

National Natural Science Foundation of China

Sichuan Cancer Hospital

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01370

Reference51 articles.

1. Cancer statistics, 2022